These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
81 related articles for article (PubMed ID: 19957536)
1. Overview of clinical studies and liposomal formulations of hamycin. Bhopale GM Hindustan Antibiot Bull; 2007 Feb-2008 Nov; 49-50(1-4):1-4. PubMed ID: 19957536 [TBL] [Abstract][Full Text] [Related]
2. Mannosylated liposomes as carriers for hamycin in the treatment of experimental aspergillosis in Balb/C mice. Moonis M; Ahmad I; Bachhawat BK J Drug Target; 1993; 1(2):147-55. PubMed ID: 8069553 [TBL] [Abstract][Full Text] [Related]
3. Is there a role for polyenes in treating invasive mycoses? Cornely OA; Vehreschild JJ; Ullmann AJ Curr Opin Infect Dis; 2006 Dec; 19(6):565-70. PubMed ID: 17075332 [TBL] [Abstract][Full Text] [Related]
4. Liposomal hamycin in the control of experimental aspergillosis in mice: relative toxicity, therapeutic efficacy and tissue distribution of free and liposomal hamycin. Moonis M; Ahmad I; Bachhawat BK Indian J Biochem Biophys; 1992 Aug; 29(4):339-45. PubMed ID: 1427960 [TBL] [Abstract][Full Text] [Related]
5. Selecting antifungal agents for the treatment of invasive fungal infections in patients with renal failure. Moudgal VV; Sobel JD Curr Opin Investig Drugs; 2004 Aug; 5(8):873-8. PubMed ID: 15600244 [TBL] [Abstract][Full Text] [Related]
6. Liposomal amphotericin B for the treatment of severe fungal infection. Michaud D Dynamics; 2001; 12(1):17-21. PubMed ID: 11982230 [TBL] [Abstract][Full Text] [Related]
7. Use of liposomal amphotericin B in bone marrow transplant. Sastry PS; Parikh PM; Kulkarni PS; Bhagwat R; Gadade H J Postgrad Med; 2005; 51 Suppl 1():S49-52. PubMed ID: 16519256 [TBL] [Abstract][Full Text] [Related]
8. Changing strategies for the management of invasive fungal infections. Rapp RP Pharmacotherapy; 2004 Feb; 24(2 Pt 2):4S-28S; quiz 29S-32S. PubMed ID: 14992487 [TBL] [Abstract][Full Text] [Related]
9. Liposomal hamycin: reduced toxicity and improved antifungal efficacy in vitro and in vivo. Mehta RT; McQueen TJ; Keyhani A; Lopez-Berestein G J Infect Dis; 1991 Nov; 164(5):1003-6. PubMed ID: 1940451 [TBL] [Abstract][Full Text] [Related]
10. Management of fungal infections following allogeneic stem cell transplantation. Narimatsu H; Kami M Expert Rev Anti Infect Ther; 2008 Jun; 6(3):373-84. PubMed ID: 18588501 [TBL] [Abstract][Full Text] [Related]
11. [Clinical comparative studies of the effectiveness of polyfungin and nystatin Polfa in the treatment of infections of the skin and mucous membranes caused by yeast-like fungi]. Bienias L; Ruszczak Z; Kurnatowska A; Kwaśniewska Przegl Dermatol; 1976; 63(5):673-8. PubMed ID: 794932 [No Abstract] [Full Text] [Related]
12. Current and future therapy of invasive fungal infections. Andriole VT Curr Clin Top Infect Dis; 1998; 18():19-36. PubMed ID: 9779349 [TBL] [Abstract][Full Text] [Related]
13. [Clinical trials in dermatology. Evaluation of the tolerability and efficacy of a topical antifungal agent in the treatment of superficial mycoses]. Queille-Roussel C; Dahan C; Duteil L; Schaefer H; Revuz J; De Prost Y; Guillaume JC; Ortonne JP; Czernielewski J Therapie; 1991; 46(3):201-4. PubMed ID: 1792652 [TBL] [Abstract][Full Text] [Related]
15. [Epidemiology and therapy of mycotic infections in immunocompromised host with special regard to the role of lipid formulations of amphotericin B]. Viscoli C; Castagnola E Recenti Prog Med; 1999 Oct; 90(10):545-57. PubMed ID: 10592741 [TBL] [Abstract][Full Text] [Related]
16. Recent approaches to antifungal therapy for invasive mycoses. Mathew BP; Nath M ChemMedChem; 2009 Mar; 4(3):310-23. PubMed ID: 19170067 [TBL] [Abstract][Full Text] [Related]
17. Lipid formulations of amphotericin B. Dix SP; Andriole VT Curr Clin Top Infect Dis; 2000; 20():1-23. PubMed ID: 10943516 [TBL] [Abstract][Full Text] [Related]